Equities

Consun Pharmaceutical Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Consun Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)18.09
  • Today's Change0.09 / 0.50%
  • Shares traded1.01m
  • 1 Year change+124.44%
  • Beta0.6633
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Consun Pharmaceutical Group Ltd is a company principally engaged in manufacturing and sales of pharmaceutical products. The Company operates its businesses through two segments. Consun Pharmaceutical segment is mainly engaged in manufacturing and sells of modern Chinese medicines and medical contrast medium. Yulin Pharmaceutical segment is mainly involved in manufacturing and sells of traditional Chinese medicines. The Company's products include kidney medicines, gynaecology and paediatrics medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines and others. The Company mainly operates its businesses in the domestic market.

  • Revenue in HKD (TTM)3.70bn
  • Net income in HKD1.14bn
  • Incorporated2010
  • Employees3.07k
  • Location
    Consun Pharmaceutical Group Ltd71 Dongpeng Avenue, East SectionEconomic and Technological DevelopmentGuangzhou Luogang DistrictGUANGZHOU 510760ChinaCHN
  • Phone+86 2 082016888
  • Fax+86 2 082017468
  • Websitehttps://www.chinaconsun.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hbm Holdings Ltd904.42m571.13m10.17bn210.0015.794.2017.0011.240.74060.74061.142.780.38566.3232.645,797,568.0024.77-42.8730.77-53.2492.9596.1264.25-292.586.0228.630.1857---57.4347.71-87.81---55.31--
China Traditional Chinese Med Hldg CoLtd17.65bn-299.94m10.27bn15.58k--0.438111.290.5819-0.0596-0.05963.514.660.43261.591.711,053,804.00-0.933.48-1.425.2447.6654.69-2.157.391.519.550.133321.27-8.902.89-95.79-49.14-15.28-48.82
Fujian Haixi Pharmaceuticals Co Ltd-100.00bn-100.00bn10.74bn--------------------------------------------------47.39--15.86------
Luye Pharma Group Ltd6.99bn449.57m10.79bn5.12k22.590.61046.731.540.11950.11951.864.420.20832.422.371,356,462.001.911.983.263.1666.8568.379.158.041.242.350.42270.00-1.33-0.9503-11.40-19.50-10.95--
Guangzhou Innogen Pharmaceutl Grp Co Ltd-100.00bn-100.00bn12.76bn105.00--15.00----------1.84------------------------3.39--0.0769------76.18------
Everest Medicines Ltd964.16m-746.10m13.86bn722.00--2.89--14.38-2.31-2.312.9813.570.168413.973.041,449,858.00-13.03-29.28-14.21-31.6769.92---77.38-1,040.865.43--0.1577--461.16---23.32--16.96--
CF PharmTech Inc684.00m31.43m14.21bn574.00452.4113.10138.3620.780.07630.07631.662.64----------------80.18--4.60--1.89--0.076--9.23---33.53------
Sihuan Pharmaceutical Holdings Group Ltd2.38bn-91.33m14.91bn2.77k--3.02--6.28-0.0098-0.00980.25750.54020.18941.493.86890,789.90-3.05-3.60-5.01-5.0566.2973.13-16.08-19.741.61-1.360.1606--2.18-7.96-301.10---20.583.60
Consun Pharmaceutical Group Ltd3.70bn1.14bn15.22bn3.07k13.593.1312.494.111.331.334.315.780.56422.3512.331,169,558.0017.6014.7124.6722.8276.6275.0431.2029.563.32--0.051740.9314.5611.4216.0562.72-9.5425.83
Ascletis Pharma Inc2.68m-292.85m17.42bn208.00--7.48--6,507.62-0.2994-0.29940.00282.200.00110.266811.5911,590.66-12.10-8.46-12.73-8.8036.217.91-10,937.78-522.1214.53--0.0023---97.73-62.52-107.95---40.26--
Zai Lab Ltd3.45bn-1.62bn17.59bn1.87k--2.90--5.10-1.52-1.523.215.370.41193.196.53---19.29-33.80-27.61-39.1261.5264.07-46.83-186.772.68--0.2108--49.5998.3823.17--32.19--
Vigonvita Life Sciences Co Ltd-100.00bn-100.00bn18.44bn---------------------------------------------------94.07---1,848.73------
Ab&B Bio Tech Co Ltd JS366.68m-254.18m20.26bn583.00--531.53--55.26-0.646-0.6460.9320.0969----------------67.29---69.32--0.3162-9.490.9646--397.65--39.09------
Data as of Feb 13 2026. Currency figures normalised to Consun Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

14.65%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 02 Feb 202638.88m4.58%
The Vanguard Group, Inc.as of 04 Feb 202618.13m2.14%
FIAM LLCas of 02 Feb 202614.34m1.69%
Goldman Sachs Asset Management LPas of 12 Feb 202610.57m1.25%
Dimensional Fund Advisors LPas of 30 Nov 202510.10m1.19%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20259.26m1.09%
APG Asset Management NVas of 31 Dec 20246.91m0.81%
BlackRock Fund Advisorsas of 06 Feb 20265.94m0.70%
Grantham, Mayo, Van Otterloo & Co. LLCas of 30 Nov 20255.64m0.67%
Robeco Institutional Asset Management BVas of 31 Dec 20254.63m0.55%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.